Панама - Енглески - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios stein, s.a. - sulfasalazina - sulfasalazina....500.000 mg

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

bryant ranch prepack - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and b) for the prolongation of the remission period between acute attacks of ulcerative colitis. sulfasalazine tablets are contraindicated in: patients with intestinal or urinary obstruction, patients with porphyria as sulfonamides have been reported to precipitate an acute attack, patients hypersensitive to sulfasalazine, its metabolites, sulfonamides, or salicylates. none reported.

Израел - Енглески - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sulfasalazine - tablets enteric coated - sulfasalazine 500 mg - sulfasalazine - sulfasalazine - for active rheumatoid arthritis which is not controlled by antiinflammatory drugs.ulcerative colitis, crohn's disease, pyoderma gangrenosum.

Израел - Енглески - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sulfasalazine - tablets - sulfasalazine 500 mg - sulfasalazine - sulfasalazine - treatment of ulcerative colitis and crohn's disease.

Малта - Енглески - Medicines Authority

p & d pharmaceuticals limited - sulfasalazine - oral suspension - sulfasalazine 250 mg/5ml - antidiarrheals, intestinal antiinflammatory/antiinfective agents

Малта - Енглески - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - sulfasalazine - oral suspension - sulfasalazine 250 mg/5ml - antidiarrheals, intestinal antiinflammatory/antiinfective agents

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

biomarin pharmaceutical inc. - elosulfase alfa (unii: odj69jzg85) (elosulfase alfa - unii:odj69jzg85) - elosulfase alfa 5 mg in 5 ml - vimizim (elosulfase alfa) is indicated for patients with mucopolysaccharidosis type iva (mps iva; morquio a syndrome). none pregnancy exposure registry there is a morquio a registry that collects data on pregnant women with mps iva who are treated with vimizim.  contact mars@bmrn.com or call 1-800-983-4587 for information and enrollment. risk summary available data from published case reports and postmarketing experience with vimizim use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, no effects on embryo-fetal development were observed in rats given daily administration of elosulfase alfa up to 33 times the human steady-state auc (area under the concentration-time curve) at the recommended human weekly dose premating and through the period of organogenesis. no effects on embryo-fetal development were observed in rabbits given daily administration of elosulfase alfa at doses up

Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

krka d.d. - sulfasalazine - tablets gastro-resistant - 500mg

Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

krka d.d. - sulfasalazine - tablets gastro-resistant - 500mg

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone; maize starch - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: salazopyrin en-tabs are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).